17 completed. 17 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 17 |
| Phase 3 | 3 | Completed 3 |
Follow Hypertrophic Cardiomyopathy: new trials by email Literature Review of Hypertrophic Cardiomyopathy trials Research Report on Hypertrophic Cardiomyopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy Trientine, Placebo - Hypertrophic Cardiomyopathy | Phase 2 | Completed | Manchester University NHS Foundation Trust | 154 | 2020-12-01 | 2025-09-29 |
| Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy Lifestyle, Sacubitril/Valsartan - Hypertrophic Cardiomyopathy | Phase 2 | Completed | Newcastle University | 168 | 2019-05-03 | 2022-11-28 |
| Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy Sacubitril/Valsartan, Lifestyle - Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Completed | Newcastle-upon-Tyne Hospitals NHS Trust | 168 | 2019-04-01 | 2022-05-09 |
| A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM mavacamten - Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Completed | Bristol-Myers Squibb | 314 | 2018-09-27 | 2026-02-20 |
| The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy. Metoprolol Succinate, Placebo oral capsule - Hypertrophic Cardiomyopathy | Phase 2 | Completed | Steen Hvitfeldt Poulsen | 30 | 2018-05-01 | 2021-03-29 |
| Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER mavacamten - Hypertrophic Cardiomyopathy | Phase 2 | Completed | Bristol-Myers Squibb | 13 | 2018-04-26 | 2025-01-09 |
| Hypertrophic Cardiomyopathy Symptom Release by BX1514M Treatment BX1514M, Placebo, Walk distance test - Hypertrophic Cardiomyopathy | Phase 2 | Completed | University Hospital, Bordeaux | 38 | 2015-10-07 | 2026-05-14 |
| Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM Valsartan, Placebo - Hypertrophic Cardiomyopathy | Phase 2 | Completed | Carelon Research | 211 | 2014-03-01 | 2021-01-11 |
| Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy Losartan, Placebo - Hypertrophic Cardiomyopathy | Phase 2 | Completed | Henning Bundgaard | 130 | 2011-11-01 | 2014-07-09 |
| Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy losartan, placebo - Hypertrophic Cardiomyopathy | Phase 2 | Completed | Massachusetts General Hospital | 20 | 2007-02-01 | 2013-09-05 |
| Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy Perhexiline/Placebo - Hypertrophic Cardiomyopathy | Phase 2 | Completed | University Hospital Birmingham | 44 | 2006-12-01 | 2010-11-04 |
| Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem Diltiazem, Placebo - Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Completed | Brigham and Women's Hospital | 39 | 2006-01-01 | 2015-04-07 |
| Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study trans-right ventricular alcohol septal ablation (TRVASA) - Hypertrophic Cardiomyopathy | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 12 | 2002-04-01 | 2008-03-04 |
| Pirfenidone to Treat Hypertrophic Cardiomyopathy Pirfenidone - Hypertrophic Cardiomyopathy | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 50 | 2001-02-01 | 2008-03-04 |
| Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle Pacemaker therapy - Hypertrophic Cardiomyopathy | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 50 | 1999-11-01 | 2008-03-04 |
| A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy pacemaker implantation, percutaneous transluminal septal ablation (PTSA) - Hypertrophic Cardiomyopathy | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 70 | 1999-08-01 | 2006-07-04 |
| Study of Blood Flow in Heart Muscle Magnetic resonance imaging - Coronary Disease, Healthy | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 249 | 1997-08-01 | 2008-03-04 |
Cardiomyopathy, Hypertrophic (17) · Arrhythmias, Cardiac (1) · Cardiomyopathies (1) · Cardiovascular Diseases (1) · Cicatrix (1) · Coronary Artery Disease (1) · Coronary Disease (1) · Fibrosis (1) · Heart Diseases (1) · Hypertrophy (1) · Hypertrophy, Left Ventricular (1) · Ischemia (1) · Myocardial Ischemia (1) · Ventricular Dysfunction, Left (1) · Ventricular Outflow Obstruction (1)
Aortic Stenosis, Subvalvular (17) · Aortic Valve Disease (17) · Aortic Valve Stenosis (17) · Heart Valve Diseases (17) · Cardiomyopathies (16) · Cardiovascular Diseases (16) · Heart Diseases (16) · Pathological Conditions, Signs and Symptoms (4) · Pathologic Processes (2) · Pathological Conditions, Anatomical (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiomegaly (1) · Hypertrophy (1) · Vascular Diseases (1)
Losartan (2) · MYK-461 (2) · sacubitril and valsartan sodium hydrate drug combination (2) · Angiotensin Receptor Antagonists (1) · Diltiazem (1) · Ethanol (1) · Magnetic Resonance Spectroscopy (1) · Metoprolol (1) · Perhexiline (1) · Trientine (1) · Valsartan (1) · pirfenidone (1)
National Heart, Lung, and Blood Institute (NHLBI) (5) · Bristol-Myers Squibb (2) · Brigham and Women's Hospital (1) · Carelon Research (1) · Henning Bundgaard (1) · Manchester University NHS Foundation Trust (1) · Massachusetts General Hospital (1) · Newcastle University (1) · Newcastle-upon-Tyne Hospitals NHS Trust (1) · Steen Hvitfeldt Poulsen (1) · University Hospital Birmingham (1) · University Hospital, Bordeaux (1)
United States (10) · United Kingdom (5) · Denmark (3) · France (2) · Germany (2) · Italy (2) · Belgium (1) · Canada (1) · Czechia (1) · Israel (1) · Netherlands (1) · Poland (1) · Portugal (1) · Serbia (1) · Spain (1)
Carolyn Y Ho, MD (1) · Carolyn Y. Ho, MD (1) · Chris Miller (1) · Djordje Jakovljevic, PhD (1) · Dr Djordje G Jakovljevic (1) · Michael A Fifer, MD (1) · Michael Frenneaux, MD (1) · Morten Kvistholm Jensen, MD, PhD (1) · Steen Hvitfeldt Poulsen, MD (1) · Torsten Bloch Rasmussen, MD, PhD (1)
PMID 24621999, PMID 25533774, PMID 12957437, PMID 18403758, PMID 20837938, PMID 20921440, PMID 22075468, PMID 22932717, PMID 24361242, PMID 24674997, PMID 25176015, PMID 25533966, PMID 26661322, PMID 26874390, PMID 26898633, PMID 27590665, PMID 28306757, PMID 28547861, PMID 28662936, PMID 28912187, PMID 29249422, PMID 29321131, PMID 29754651, PMID 31813281, PMID 34556856, PMID 34915981, PMID 35450573, PMID 37137675, PMID 37672268, PMID 38176782, PMID 38591260, PMID 39087355, PMID 39217450, PMID 40042824, PMID 40340372, PMID 42455121, PMID 42636950, PMID 42858009, PMID 7641357
K23HL078901 (1), P50HL112349 (1)